Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug CTX-187 takes aim at stubborn bacterial infections

NCT ID NCT07708116

Recruiting now Disease control Sponsor: Centauri Therapeutics Limited Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This first-in-human trial tests an experimental drug called CTX-187 for safety and tolerability. It starts with healthy volunteers to assess single and multiple doses, then moves to patients with bronchiectasis who have a chronic Pseudomonas infection. The goal is to see if the drug is safe enough to study further.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental drug called CTX-187
What this could lead to
If safe and effective, CTX-187 could offer a new treatment option for hard-to-treat bacterial infections, especially in people with bronchiectasis and chronic Pseudomonas.
What could go wrong
This is a very early Phase 1 trial focused on safety, not yet on how well it works. The drug may cause side effects or fail to show benefit in later studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BACTERIAL INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bacterial infectious disease bronchiectasis Pseudomonas infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BACTERIAL INFECTIONS BRONCHIECTASIS ADULT BRONCHIECTASIS WITH PSEUDOMONAS AERUGINOSA COLONIZATION

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • ICON Clinic, location GRQM

    RECRUITING

    Groningen, 9728, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.